Depression - Pipeline Review, H1 2019

Publisher Name :
Date: 23-May-2019
No. of pages: 558
Inquire Before Buying

Depression - Pipeline Review, H1 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Depression - Pipeline Review, H1 2019, provides an overview of the Depression (Central Nervous System) pipeline landscape.

Depression is a mood disorder that causes a persistent feeling of sadness and loss of interest. Signs and symptoms include sleep disturbances, including insomnia or sleeping too much, changes in appetite, anxiety, agitation or restlessness and physical problems, such as back pain or headaches. Treatment includes antidepressants, mood stabilizers or antipsychotics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Depression - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Depression (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Depression (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Depression and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 1, 16, 34, 36, 2, 78, 13 and 5 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 12 and 7 molecules, respectively.

Depression (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Depression (Central Nervous System).

- The pipeline guide reviews pipeline therapeutics for Depression (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Depression (Central Nervous System) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Depression (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Depression (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Depression (Central Nervous System).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Depression (Central Nervous System) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Depression - Pipeline Review, H1 2019

Table of Contents
Introduction
Depression - Overview
Depression - Therapeutics Development
Depression - Therapeutics Assessment
Depression - Companies Involved in Therapeutics Development
Depression - Drug Profiles
Depression - Dormant Projects
Depression - Discontinued Products
Depression - Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Depression, H1 2019
Number of Products under Development by Companies, H1 2019
Number of Products under Development by Universities/Institutes, H1 2019
Products under Development by Companies, H1 2019
Products under Development by Universities/Institutes, H1 2019
Number of Products by Stage and Target, H1 2019
Number of Products by Stage and Mechanism of Action, H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019
Depression - Pipeline by Acadia Pharmaceuticals Inc, H1 2019
Depression - Pipeline by Adamed Sp zoo, H1 2019
Depression - Pipeline by Addex Therapeutics Ltd, H1 2019
Depression - Pipeline by Aequus Pharmaceuticals Inc, H1 2019
Depression - Pipeline by Alkermes Plc, H1 2019
Depression - Pipeline by Allergan Plc, H1 2019
Depression - Pipeline by Amorsa Therapeutics Inc, H1 2019
Depression - Pipeline by Anavex Life Sciences Corp, H1 2019
Depression - Pipeline by Angelini Group, H1 2019
Depression - Pipeline by Atai Life Sciences AG, H1 2019
Depression - Pipeline by Avanir Pharmaceuticals Inc, H1 2019
Depression - Pipeline by Axsome Therapeutics Inc, H1 2019
Depression - Pipeline by Azevan Pharmaceuticals Inc, H1 2019
Depression - Pipeline by Bionomics Ltd, H1 2019
Depression - Pipeline by BioXcel Therapeutics Inc, H1 2019
Depression - Pipeline by Boehringer Ingelheim GmbH, H1 2019
Depression - Pipeline by Bristol-Myers Squibb Co, H1 2019
Depression - Pipeline by Calico LLC, H1 2019
Depression - Pipeline by Celgene Corp, H1 2019
Depression - Pipeline by Cellix Bio Pvt Ltd, H1 2019
Depression - Pipeline by Celon Pharma SA, H1 2019
Depression - Pipeline by Cerecor Inc, H1 2019
Depression - Pipeline by Clera Inc, H1 2019
Depression - Pipeline by Clexio Biosciences Ltd, H1 2019
Depression - Pipeline by Delpor Inc, H1 2019
Depression - Pipeline by Denovo Biopharma LLC, H1 2019
Depression - Pipeline by Douglas Pharmaceuticals Ltd, H1 2019
Depression - Pipeline by Eisai Co Ltd, H1 2019
Depression - Pipeline by Eli Lilly and Co, H1 2019
Depression - Dormant Projects, H1 2019
Depression - Discontinued Products, H1 2019

List of Figures
Number of Products under Development for Depression, H1 2019
Number of Products under Development by Companies, H1 2019
Number of Products under Development by Universities/Institutes, H1 2019
Number of Products by Top 10 Targets, H1 2019
Number of Products by Stage and Top 10 Targets, H1 2019
Number of Products by Top 10 Mechanism of Actions, H1 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019
Number of Products by Top 10 Routes of Administration, H1 2019
Number of Products by Stage and Top 10 Routes of Administration, H1 2019
Number of Products by Molecule Types, H1 2019
Number of Products by Stage and Top 10 Molecule Types, H1 2019
  • Central Nervous System Agents Market Insights 2019, Global and Chinese Analysis and Forecast to 2024
    Published: 28-Jun-2019        Price: US 3000 Onwards        Pages: 142
    Central Nervous System Agents Market Insights 2019, Global and Chinese Scenario is a professional and in-depth study on the current state of the global Central Nervous System Agents industry with a focus on the Chinese market. The report provides key statistics on the market status of the Central Nervous System Agents manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. Overall, the report provides an in-depth insight of 2014-......
  • Global Central Nervous System Agents Industry Market Research Report
    Published: 25-Jun-2019        Price: US 2960 Onwards        Pages: 127
    The Central Nervous System Agents market revenue was xx.xx Million USD in 2014, grew to xx.xx Million USD in 2018, and will reach xx.xx Million USD in 2024, with a CAGR of x.x% during 2019-2024. Based on the Central Nervous System Agents industrial chain, this report mainly elaborates the definition, types, applications and major players of Central Nervous System Agents market in details. Deep analysis about market status (2014-2019), enterprise competition pattern, advantages and disadvantages ......
  • Delirium Global Clinical Trials Review, H1, 2019
    Published: 31-May-2019        Price: US 2500 Onwards        Pages: 253
    Delirium Global Clinical Trials Review, H1, 2019 Summary GlobalData's clinical trial report, "Delirium Global Clinical Trials Review, H1, 2019" provides an overview of Delirium clinical trials scenario. This report provides top line data relating to the clinical trials on Delirium. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country......
  • Dementia Associated With Alzheimer's Disease Global Clinical Trials Review, H1, 2019
    Published: 31-May-2019        Price: US 2500 Onwards        Pages: 266
    Dementia Associated With Alzheimer's Disease Global Clinical Trials Review, H1, 2019 Summary GlobalData's clinical trial report, "Dementia Associated With Alzheimer's Disease Global Clinical Trials Review, H1, 2019" provides an overview of Dementia Associated With Alzheimer's Disease clinical trials scenario. This report provides top line data relating to the clinical trials on Dementia Associated With Alzheimer's Disease. Report includes an overview of trial numbers an......
  • Dental Pain (Toothache/Tooth Pain) Global Clinical Trials Review, H1, 2019
    Published: 31-May-2019        Price: US 2500 Onwards        Pages: 322
    Dental Pain (Toothache/Tooth Pain) Global Clinical Trials Review, H1, 2019 Summary GlobalData's clinical trial report, "Dental Pain (Toothache/Tooth Pain) Global Clinical Trials Review, H1, 2019" provides an overview of Dental Pain (Toothache/Tooth Pain) clinical trials scenario. This report provides top line data relating to the clinical trials on Dental Pain (Toothache/Tooth Pain). Report includes an overview of trial numbers and their average enrollment in top countr......
  • Diabetic Neuropathic Pain Global Clinical Trials Review, H1, 2019
    Published: 31-May-2019        Price: US 2500 Onwards        Pages: 175
    Diabetic Neuropathic Pain Global Clinical Trials Review, H1, 2019 Summary GlobalData's clinical trial report, "Diabetic Neuropathic Pain Global Clinical Trials Review, H1, 2019" provides an overview of Diabetic Neuropathic Pain clinical trials scenario. This report provides top line data relating to the clinical trials on Diabetic Neuropathic Pain. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The ......
  • Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Global Clinical Trials Review, H1, 2019
    Published: 31-May-2019        Price: US 2500 Onwards        Pages: 94
    Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Global Clinical Trials Review, H1, 2019 Summary GlobalData's clinical trial report, "Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Global Clinical Trials Review, H1, 2019" provides an overview of Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) clinical trials scenario. This report provides top line data relating to the clinical trials on Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy). Report ......
  • Drug Addiction Global Clinical Trials Review, H1, 2019
    Published: 31-May-2019        Price: US 2500 Onwards        Pages: 733
    Drug Addiction Global Clinical Trials Review, H1, 2019 Summary GlobalData's clinical trial report, "Drug Addiction Global Clinical Trials Review, H1, 2019" provides an overview of Drug Addiction clinical trials scenario. This report provides top line data relating to the clinical trials on Drug Addiction. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical t......
  • Dysautonomia (Autonomic Dysfunction/Autonomic Neuropathy) Global Clinical Trials Review, H1, 2019
    Published: 31-May-2019        Price: US 2500 Onwards        Pages: 61
    Dysautonomia (Autonomic Dysfunction/Autonomic Neuropathy) Global Clinical Trials Review, H1, 2019 Summary GlobalData's clinical trial report, "Dysautonomia (Autonomic Dysfunction/Autonomic Neuropathy) Global Clinical Trials Review, H1, 2019" provides an overview of Dysautonomia (Autonomic Dysfunction/Autonomic Neuropathy) clinical trials scenario. This report provides top line data relating to the clinical trials on Dysautonomia (Autonomic Dysfunction/Autonomic Neuropat......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs